agents tested. Effect on selected ampicillin-resistant strains, differential sensitivity to alafosfalin among resistant strains of various types, and sensitivity of alafosfalin-insensitive E. coli and Klebsiella to other antibiotics are also discussed.
Alafosfalin (formerly alaphosphin; Ro 03-708), L-alanyl-L-1-aminoethylphosphonic acid, is a novel phosphonopeptide designed and synthesized by Hassall et al. (5) and Allen et al. (1) which inhibits the biosynthesis of bacterial cell walls by a mechanism differing from that elucidated for cell wall-active antibiotics such as /3-lactams and D-cycloserine (2, 4) . When sensitive bacteria are exposed to alafosfalin, the compound is actively transported into the cells by means of LL-dipeptide permeases and produces, by intracellular hydrolysis, alanine and aminoethylphosphonic acid. The latter acts on several steps of cell wall biosynthesis (1, 4) , thereby accounting for its antibacterial activity as well as the synergism observed with other cell wallacting antibiotics.
The present study was undertaken to evaluate the in vitro activity of alafosfalin alone and of the combinations with /8-lactams against 475 strains (11 genera) of urinary tract infection (UTI) bacteria isolated in Japan.
(The study was presented at the 26th Annual Meeting of the Japanese Society for Chemotherapy on 19 June 1978.) MATERIALS AND METHODS Test organisms. All the organisms used were clinical isolates at 18 hospitals in the Kanto District of Japan. They were recovered in June to September 1976 from used Urotubes (Roche Products Ltd., Welwyn, England), identified by using Enterotubes and Oxi/Ferm tubes as reported previously (8, 9) , and tested within 6 months. A total of 475 strains were used for the present study: 144 Escherichia coli, 9 Citrobacter sp., 46 Proteus sp., 16 Enterobacter sp., 85 Serratia sp., 29 Klebsiella sp., 54 Pseudomonas sp., 15 Acinetobacter sp., 4 Achromobacter sp., 2 Akcaligenes sp., 1 Flavobacter sp., 37 Staphylococcus sp., and 33 Streptococcus faecalis (enterococci). All strains were inoculated from an agar slant to Tryptosoy broth (lot no. 5L038; Nissui) cultured overnight at 37°C and used for the test by dilution with sterile saline.
Determination of minimal inhibitory concentration (MIC). Susceptibility to alafosfalin, penicillin G (PCG), ampicillin (AMP), and cephazolin (CEZ), and to combinations of it and these f,-lactams, was determined by the agar dilution method.
Alafosfalin was obtained from Roche, and the preparations of (1-lactams used were as foliows: penicillin G (lot no. GLD42; Meiji Seika Kaisha Ltd.), AMP sodium salt (PA-S; lot no. 54-36), and CEZ sodium (Cefamezin, lot no. ZH-7240; Fujisawa Pharmaceutical Co., Ltd.).
Since it is known that alafosfalin is antagonized by the presence of small peptides and to a lesser extent by alanine and glutamic acid (2), a defined minimal medium, staphylococcal defined medium (5), was used throughout the present study. Test organisms grown overnight were inoculated onto the surface of a staphylococcal defined medium agar plate containing each drug at 14 different concentrations by using a replicating device (Multi-Typing Apparatus; Rikoh Shoji Co.).
The replicator delivered approximately 2 to 3 Al of a 102 (for gram-positive cocci) or 10; (for gram-negative rods) dilution of an original suspension (10W cells per ml) of each strain in Tryptosoy broth (overnight culture). The MIC was defined as the lowest concentration of antibiotics or antibacterial agents that prevented any colony from growing after 18 h of incubation at 37°C. A test of significance for differences in the MIC distribution of each drug with each strain or genus was performed by the rank sum test (10) . Unless otherwise stated, strains against which the MIC of a drug was >25 ug/ml were judged as resistant to the antibiotic tested.
The fractional inhibitory concentration (FIC) was calculated by the method of Elion et al. (6) When results of all UTI isolates tested were combined regardless of genus, alafosfalin was active against 74% of the gram-positive cocci, 65% of the gram-negative bacilli, and 66% of the total UTI isolates collected (8) .
Susceptibility of antibiotic-resistant strains to alafosfalin. More than 87% of the gram-negative bacteria used were found to be resistant to one or more commonly used antibacterial agents (MIC _ 25 .Ig/ml), e.g., AMP, CEZ, kanamycin, gentamicin, tetracycline, or nalidixic acid. The susceptibility to alafosfalin of such resistant isolates was calculated for each genus (Table 2 ). It was found that the MIC50 of alafosfalin against strains tested in seven genera was below 12.5 ,Ag/ml, with the exception of Staphylococcus resistant to other antibiotics. The strains sensitive to alafosfalin' occupied almost 70% of the total isolates tested. Three different patterns in the susceptibility to alafosfalin of such resistant strains were found. Thus: (i) in E. coli, S. faecalis, and Enterobacter sp., alafosfalin was equally active against strains either resistant or sensitive to any antibiotics; (ii) in Staphylococcus sp. and Serratia sp., antibiotic-susceptible strains were significantly more susceptible to alafosfalin than were strains which were resistant to at least one of the antibiotics used in this study; and (iii) alafosfalin was selectively more active against a certain type of resistant strain (i.e., tetracycline-resistant strains of Klebsiella and E. coli).
When the relationship of resistant markers to alafosfalin resistance was looked at with E. coli, it was noted that most of the strains multiresis-ANTIMICROB. AGENTS CHEMOTHER.
tant to AMP, CEZ, kanamycin, and nalidixic acid were also resistant to alafosfalin (67%). The percentages ofkanamycin-resistant and nalidixic acid-resistant E. coli were high in those strains which were alafosfalin resistant. A similar situation was found with those strains of Klebsiella resistant to at least one of the fl-lactams tested.
On the other hand, with Citrobacter and Enterobacter, most of the kanamycin-resistant strains were sensitive to alafosfalin. With Staphylococcus sp., kanamycin-resistant strains were also, in general, less associated with alafosfalin resistance, although the high resistance to alafosfalin by (i) strains resistant to ,B-lactams tested, resistant to erythromycin, and resistant to tetracycline and (ii) strains resistant to tetracycline alone was noticeable. With S. faecalis, it was found that the most frequently occurring resistant strains, i.e., those resistant to kanamycin and gentamicin, were all sensitive to alafosfalin.
The above results indicated that alafosfalin displayed the lowest cross resistance with the other common antibiotics examined, including the /?-lactams. Thus 51 of the 144 E. coli isolates tested were AMP resistant (MIC ' 25 ,ug/ml; Table 2 ). The MIC distribution to alafosfalin in these and the AMP-sensitive strains was identical ( Fig. 1) , whereas CEZ was clearly less active against AMP-resistant strains, indicating a degree of cross resistance. This was more clearly seen in the population analysis of typical resistant strains (Fig. 2) . AMP-resistant strain no. 154 contained a population of 10' CEZ-resistant clones, which contrasted with a value of 10'-in AMP-sensitive strains (e.g., strain no. 437). The alafosfalin-resistant population was less than 10-8, regardless of susceptibility to AMP. Furthermore, alafosfalin in combination with CEZ decreased the resistant population in strain no. 154 to the level of the AMP-sensitive strains (no. 154-A and 154-B in Fig. 2c ). Similar effects were also seen with the AMP-susceptible strain no. 437 (Fig. 2b) , though to a lesser extent. The frequency of resistant clones to alafosfalin itself (10-8 to 10-9) in alafosfalin-sensitive strains was much less than that (10-5 to 10-6) reported for another phosphonic acid containing the antibiotic fosfomycin (7). Figure 3 shows the MIC distribution of the combinations in comparison with that of the f)-lactam antibiotics alone. A clear potentiation of each ,B-lactam was observed in every combination at both ratios against those strains which were either susceptible to alafosfalin or almost insensitive to these ,B-lactams. On the other hand, no synergism was 6.25->100 12.5 >100 0.78->100 3.13 25 3.13->100 12.5 >100 0.78->100 6.25 >100 0.39->100 >100 >100 6.25->100 >100 >100 25->100 >100 >100
1.56->100 25 >100 0.1->100 >100 >100 0.1->100 25 >100 25->100 >100 >100 0.39->100 >100 >100
3.13->100 3.13 >100 3.13->100 3.13 >100 evident with gram-positive cocci. The difference between the combination and the antibiotic alone was found to be significant in many cases, by the rank sum test (10) ( Table 3) . Table 4 shows the percentage of total strains against which the FIC index was ' 0.5. Synergy of up to 31% was observed between alafosfalin and two ,8-lactams in E. coli, Klebsiella, Enterobacter, and Citrobacter. Total synergistic cases, i.e., strains against which the index was <1.0 (B in Table 4 ), were observed in more than 55% of strains in these genera when a combination of AMP and alafosfalin (4:1) was used. The synergy was less remarkable in Serratia and S. faecalis. It is to be noted that synergy by the alafosfalin combination with the ,B-lactams was observed in up to 54% of strains belonging to indole-positive Proteus and of nonfermentative rods ( (2) . This fact may reasonably suggest that it would exert its best activity in vivo in a poor nutritional environment such as urine. Should this prove correct, the present results indicate that the majority of common pathogens in UTI, including E. coli, Klebsiella, Citrobacter, Enterobacter, and Serratia, would be susceptible to alafosfalin at concentrations of <25 j,g/ml, easily achieved by a single oral administration (3) . VOL. 16, 1979 on November 2, 2017 by guest http://aac.asm.org/ (Tables 3 and 4 ; Fig. 3 ), confirming the previous report (1, 2) . It is suggested from the absence of cross resistance between alafosfalin and ,f-lactams (Table 2 ; Fig. 1 ) that the proposed multiblockade of cell wall synthesis could contribute to this phenomenon (1, 4) . The extent of the synergism varied with the strains tested, but in general more than 50% of the susceptible strains showed FIC indexes of less than 1.0 (Table 4) . It is noteworthy that a minority of strains insensitive to alafosfalin alone also exhibited a clear potentiation with f-lactams so as to widen the susceptible spectrum. This fact leads one to anticipate that, if any of the ,Blactams active against these species was used as the partner, a higher activity could be expected in combination with alafosfalin. That more than 70% of UTI isolates resistant to established antibiotics are susceptible to alafosfalin is a great advantage to the phosphonopeptide.
Among 144 E. coli strains examined, 11 strains (7.6%) were found to be naturally resistant to alafosfalin. The mechanisms of the resistance should be clarified for better clinical use of this unique antibacterial agent. Our preliminary study showed that the uptake of alafosfalin in these naturally resistant strains was roughly one-fourth to one-half of that in the susceptible strains. By contrast, the resistant clones selected in the laboratory did not show any uptake of the drug. Despite the level of natural resistance, the high activity and extremely low incidence of cross resistance with existing agents suggest a potential clinical role for alafosfalin either alone or as a combination product with 8-lactam antibiotics.
